<DOC>
	<DOCNO>NCT00531752</DOCNO>
	<brief_summary>The purpose study determine whether PF-03654746 effective treatment Adult Attention Deficit Hyperactivity Disorder ( ADHD ) . This randomized , double-blind , crossover study adult ADHD receive 3 week treatment PF-03654746 , either low dose ( 1 mg ) , flexible dose ( 0.50 mg titrate 2 mg ) , 3 week placebo . A washout period separate 2 treatment period . Participants require washout prior ADHD medication enter study . Participants require come site 10 visit approximately 10-week period .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Two Doses PF-03654746 Adults With Attention Deficit Hyperactivity Disorder ( ADHD ) .</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Subjects diagnosis Attention Deficit Hyperactivity Disorder , base clinical assessment interview . Male female outpatient . Subjects diagnosis Attention Deficit Hyperactivity Disorder , base clinical assessment interview . Female subject must nonchildbearing potential . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular ( include hypertension ) , hepatic , neurologic , allergic disease . Current lifetime history psychosis bipolar disorder ; current anxiety disorder ( exception social specific phobia ) , substance abuse dependence past 6 month . Current episode Major Depression episode within last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>